cGAS-STING signaling and function in metabolism and kidney diseases

作     者：Juli Bai Feng Liu Juli Bai;Feng Liu

作者机构：Department of PharmacologyUniversity of Texas Health at San AntonioSan AntonioTX 78229USA National Clinical Research Center for Metabolic DiseasesMetabolic Syndrome Research CenterKey Laboratory of Diabetes ImmunologyMinistry of Educationand Department of Metabolism and EndocrinologyThe Second Xiangya Hospital of Central South UniversityChangsha 410011China 

出 版 物：《Journal of Molecular Cell Biology》 (分子细胞生物学报（英文版）)

年 卷 期：2021年第13卷第10期

页      面：728-738页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 10[医学] 

基　　金：supported in part by grants from the National Natural Science Foundation of China(NSFC,81730022 and 81870601) Innovative Basic Science Awards of American Diabetes Association(1-19-IBS-147). 

主　　题：cGAS STING obesity NAFLD NASH AKI CDK 

摘      要：The cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)signaling pathway senses the presence of cytosolic DNA and,in turn,triggers downstream signaling to induce the expression of inflammatory and type I interferon genes in immune cells.Whereas the innate immune function of the cGAS-STING pathway is well studied over the past years,emerging evidence suggests that this signaling pathway may have additional functions beyond innate immune surveillance.Consistent with this notion,dysregulation of the cGAS-STING signaling pathway in adipocytes,hepatocytes,and renal proximal tubule epithelial cells are associated with metabolic dysfunction,impaired energy homeostasis,and kidney diseases.In this review,we summarize current understanding of the cGAS-STING pathway in several metabolic diseases such as obesity,insulin resistance,alcoholic and nonalcoholic fatty liver diseases,as well as acute kidney injury and chronic kidney disease.We also review the interaction between the cGAS-STING pathway and lipid metabolism.Lastly,we discuss potential mechanisms by which cGAS-STING signaling regulates metabolism and point toward future avenues of research targeting the cGAS-STING pathway as possible means to treat common metabolic disorders.